

Our Ref.: 2551-28  
US104.LOC.KV

# ***U.S. PATENT APPLICATION***

***Inventor(s):*** Stephen A. LOCARNINI  
Angeline I. BARTHOLOMEUSZ  
Thein T. AYE  
Robert A. deMAN

***Invention:*** VIRAL VARIANTS AND METHODS FOR DETECTING SAME

***NIXON & VANDERHYE P.C.***  
***ATTORNEYS AT LAW***  
***1100 NORTH GLEBE ROAD***  
***8<sup>TH</sup> FLOOR***  
***ARLINGTON, VIRGINIA 22201-4714***  
***(703) 816-4000***  
***Facsimile (703) 816-4100***

## ***SPECIFICATION***

## VIRAL VARIANTS AND METHODS FOR DETECTING SAME

Insert  
AA1

- 5 The present invention relates generally to viral variants exhibiting reduced sensitivity to particular agents and/or reduced interactivity with immunological reagents. More particularly, the present invention is directed to hepatitis B variants exhibiting complete or partial resistance to nucleoside analogues and/or reduced interactivity with antibodies to viral surface components. The present invention further contemplates assays for detecting such viral variants which assays are useful
- 10 in monitoring anti-viral therapeutic regimes.

Bibliographic details of the publications numerically referred to in this specification are collected at the end of the description. Sequence Identity Numbers (SEQ ID NOs.) for the nucleotide and amino acid sequences referred to in the specification are defined following the bibliography.

15

Throughout this specification, unless the context requires otherwise, the word "comprise", or variations such as "comprises" or "comprising" or the term "includes" or variations thereof, will be understood to imply the inclusion of a stated element or integer or group of elements or integers but not the exclusion of any other element or integer or group of elements or integers.

- 20 In this regard, in construing the claim scope, an embodiment where one or more features is added to any of claim is to be regarded as within the scope of the invention given that the essential features of the invention as claimed are included in such an embodiment.

- Specific mutations in an amino acid sequence are represented herein as "Xaa<sub>n</sub>Xaa<sub>2</sub>" where Xaa<sub>1</sub>
- 25 is the original amino acid residue before mutation, n is the residue number and Xaa<sub>2</sub> is the mutant amino acid. The abbreviation "Xaa" may be the three letter or single letter amino acid code. The amino acid residues for Hepatitis B virus DNA polymerase are numbered with the residue methionine in the motif Tyr Met Asp Asp (YMDD) being residue number 550. In the priority document, Australian Patent Application No. PO3519, filed 8 November 1996, the same
- 30 methionine was designated residue 530. The amino acid residues for the DNA polymerase referred to in this specification have been re-numbered accordingly.

- 2 -

Hepatitis B Virus (HBV) can cause debilitating disease conditions and can lead to acute liver failure. HBV is a DNA virus which replicates *via* an RNA intermediate and utilizes reverse transcription in its replication strategy (1). The HBV genome is of a complex nature having a partially double stranded DNA structure with overlapping open reading frames encoding surface, core, polymerase and X genes. The complex nature of the HBV genome is represented in Figure 1.

The presence of an HBV DNA polymerase has led to the proposition that nucleoside analogues could act as effective anti-viral agents. Examples of nucleoside analogues currently being tested are penciclovir and its oral form famciclovir (2, 3, 4, 5) and lamivudine (6,7). There is potential for such agents to be used in the treatment of chronic HBV infection.

Peniclovir has been recently shown to have potent inhibitory activity against duck HBV DNA synthesis *in vitro* and has been shown to inhibit HBV DNA polymerase-reverse transcriptase activity *in vitro* (8,9). Similarly, oral famciclovir has been demonstrated to inhibit intra-hepatic replication of duck HBV virus *in vivo* (10). In man, famciclovir has been shown to reduce HBV DNA replication in a patient with severe hepatitis B following orthotopic liver transplantation (OLT) (11).

In work leading up to the present invention, nucleoside analogue antiviral therapy was used to control severe post-OLT recurrence of HBV infection (12). Long term therapy is mandatory where patients are immunosuppressed and the rate of HBV replication is very high. However, under such conditions, as with any long term chemotherapy of infectious agents, there is a potential for development of resistance or reduced sensitivity to the therapeutic agents employed.

25

In accordance with the present invention, the inventors have identified variants of HBV with mutations in the HBV DNA polymerase gene which to varying extents reduce the sensitivity of HBV to nucleoside analogues. The identification of these HBV variants is important for the development of assays to monitor nucleoside analogue therapeutic regimes and to screen for agents which can mask the effects of the mutation. In addition, since the HBV genome comprises a series of overlapping open reading frames, a nucleotide mutation in one open reading

- 3 -

frame can affect translation products in another open reading frame. In further accordance with the present invention, the inventors have observed mutations which reduce the interactivity of immunological reagents, such as antibodies and immune cells, to viral surface components. Such viral variants are referred to herein as "escape mutants" since they potentially escape existing  
5 immunological memory.

Accordingly, one aspect of the present invention is directed to a variant of an isolated DNA virus which replicates *via* an RNA intermediate wherein said variant comprises a nucleotide mutation in a gene encoding a DNA polymerase resulting in at least one amino acid addition, substitution  
10 and/or deletion to said DNA polymerase.

Another aspect of the present invention provides a variant of an isolated DNA virus which replicates *via* an RNA intermediate wherein said variant comprises a nucleotide mutation in a gene encoding a viral surface component resulting in at least one amino acid addition,  
15 substitution and/or deletion in said viral surface component.

Still a further aspect of the present invention is directed to a variant of an isolated DNA virus which replicates *via* an RNA intermediate at least wherein said variant comprises a nucleotide mutation in an overlapping portion of at least two open reading frames resulting in an amino acid  
20 addition, substitution and/or deletion to translation products of said open reading frames.

Preferably, the DNA virus is a hepatitis virus or a related virus and is most preferably HBV.

A "related virus" in accordance with the present invention is one related at the genetic,  
25 immunological, epidemiological and/or biochemical levels.

Preferably, the mutation in the DNA polymerase results in decreased sensitivity of the HBV to a nucleoside analogue.

30 Preferably, the mutation in the viral surface component reduces the interactivity of immunological reagents such as antibodies and immune cells to the viral surface component.

Most preferably, the viral surface component is a viral surface antigen. The reduction in the interactivity of immunological reagents to a viral surface component generally includes the absence of immunological memory to recognise or substantially recognise the viral surface component.

5

A viral variant may, in accordance with a preferred aspect of the present invention, carry mutation only in the DNA polymerase or the surface antigen or may carry a mutation in both molecules. The term "mutation" is to be read in its broadest context and includes a silent mutation not substantially affecting the normal function of the DNA polymerase or surface antigen or may be an active mutation having the effect of inducing nucleoside analogue resistance or an escape mutant phenotype. Where multiple mutations occur in accordance with the present invention or where multiple phenotypes result from a single mutation, at least one mutation must be active or the virus must exhibit at least one altered phenotype such as nucleoside analogue resistance or reduced immunological interactivity to the surface antigen.

15

Regions of the HBV polymerase show amino acid similarity with other RNA-dependent DNA polymerases and RNA-dependent polymerases (13). In this specification, reference is made to the conserved regions defined by Poch *et al* (13) as domains B and C.

20 Preferably, the mutation results in an altered amino acid sequence in the B domain and/or C domain or regions proximal thereto of the HBV DNA polymerase. The present invention does not extend to a mutation alone in the YMDD motif of the C domain of the HBV DNA polymerase although such a mutation is contemplated by the present invention if it occurs in combination with one or more mutations in another location.

25

The mutation in the viral surface component is preferably in one or more amino acid residues within the major hydrophilic regions of the protein, in particular within the amino acid sequence 118-169 of the HBV viral surface antigen and also the regions from amino acids sequence 169 to 207 which are on the external surface of the protein.

30

According to a preferred aspect of the present invention, there is provided an HBV variant

- 5 -

comprising a mutation in the nucleotide sequence encoding a DNA polymerase resulting in an amino acid addition, substitution and/or deletion in said DNA polymerase in its B domain and/or C domain or in a region proximal thereto, provided said mutation is not in the YMDD motif of the C domain alone, and wherein said variant exhibits decreased sensitivity to a nucleoside 5 analogue.

Another preferred aspect of the present invention contemplates an HBV variant comprising a mutation in the nucleotide sequence encoding a viral surface component resulting in an amino acid addition, substitution and/or deletion in said viral surface component in a region 10 corresponding to the B domain and/or C domain of HBV DNA polymerase or a region proximal to the B domain and/or C domain of HBV DNA polymerase and wherein said variant exhibits decreased interactivity of immunological reagents to said viral surface component.

Yet another preferred aspect of the present invention relates to an HBV variant comprising a 15 mutation in the nucleotide sequence encoding a viral surface component resulting in an amino acid addition, substitution and/or addition in said viral surface component in a region defined by amino acids 118 to 169 and also 169 to 207 of the HBV surface antigen or functionally equivalent region wherein said variant exhibits decreased interactivity of immunological reagents to said viral surface component.

20

Still yet another aspect of the present invention is directed to an HBV variant comprising a mutation in an overlapping open reading frame in its genome wherein said mutation is in the B and/or C domain of DNA polymerase provided that it is not in the YMDD motif of the C domain alone; and in the overlapping region corresponding to amino acids 118 to 169 and also 169 to 25 207 or equivalent of HBV surface antigen and wherein said variant exhibits decreased sensitivity to a nucleotide analogue and exhibits decreased interactivity to immunological reagents specific to HBV surface antigens.

The viral variant exhibiting reduced interactivity to immunological reagents is an escape mutant 30 since antibodies or other immunological response to HBV from a prior exposure to the virus or following vaccination are no longer effective in targeting a viral surface component since the

- 6 -

mutation has altered a B- and/or T-cell epitope on the surface antigen.

The nucleoside analogues contemplated by the present invention include penciclovir and its oral form famciclovir as well as lamivudine (3TC). Different variants may be resistant to different nucleoside analogues. For example, in one embodiment, a variant in the B domain of HBV DNA polymerase may be resistant to famciclovir whereas a variant in the C domain may be resistant to 3TC.

The B domain is considered to comprise amino acid residues 505 to 529 of HBV DNA polymerase. This sequence is represented as follows: (SEQ ID NO: 24)

S/A H P I I/V L G F R K I/L P M G V/G G L S P F L L A Q F.

Reference to the B domain includes reference to proximal regions which includes up to about 20 amino acids on either side of the domain. Preferably, the mutation is in one or more of the following amino acids: (SEQ ID NO: 25)

Q/K T Y/F G R/W K L H L Y/L S/A H P I I/V L G F R K I/L P M G V/G  
G L S P F L L A Q F T S A I C/L S

The C domain comprises amino acids 546 to 556 as follows: (SEQ ID NO: 26)

A/V F S/A Y M D D V/L/M V L G

This includes the Y M D D domain in which the methionine residue is considered residue 550 (formally regarded as residue number 530). The residue numbering in this specification has been adjusted according to the new numbering system where the methionine of Y M D D is 550.

Reference to the C domain includes proximal regions of up to 20 amino acids either side of the domain.

The term "resistance" is used in its most general sense and includes total resistance or partial resistance or decreased sensitivity to a nucleoside analogue.

5 HBV.

10 include one or more of Asp144Glu and/or Gly145Arg. These correspond to positions 498 and 499 of DNA polymerase, respectively. More preferably, the variants contain two or more of the above-mentioned mutations.

15 a multiphenotypic mutation rendering the DNA polymerase resistant to nucleoside analogues and  
an altered surface antigen such that it has reduced interactivity with antibodies to HBV surface  
antigen. The mutation is ~~G498E~~<sup>R/W499E</sup> in the DNA polymerase open reading frame as D144E and  
G145R in the surface antigen. This results from a double mutation in nucleotide numbers 226  
and 227 of SEQ ID NO:17 to G and A. The polymerase protein of HBV is also similar to the  
20 DNA polymerase of Herpes Simplex Virus (HSV) (see Figure 3 for alignment). A mutation  
(Gly841Cys) in the HSV polymerase gene was selected for in the presence of famciclovir (15).  
This mutation occurs in the same position as the G498E mutation of the HBV polymerase.

25 a nucleotide sequence having at least 60% similarity thereto and which carries a double mutation in the amino acid sequence of DNA polymerase and the HBV surface antigen. Accordingly, the present invention is directed to an HBV having the nucleotide sequence as set forth in SEQ ID NO:17 or a derivative thereof having a single or multiple nucleotide addition, substitution and/or deletion thereto such as a nucleotide sequence having at least 60% similarity to SEQ ID NO:17.

30 A derivative includes parts, fragments, portions and homologues of SEQ ID NO:17. This aspect of the present invention also extends to a nucleotide sequence capable of hybridizing under low



stringency conditions at 42°C to SEQ ID NO:17.

Reference herein to a low stringency at 42°C includes and encompasses from at least about 1% v/v to at least about 15% v/v formamide and from at least about 1M to at least about 2M salt for hybridisation, and at least about 1M to at least about 2M salt for washing conditions. Alternative stringency conditions may be applied where necessary, such as medium stringency, which includes and encompasses from at least about 16% v/v to at least about 30% v/v formamide and from at least about 0.5M to at least about 0.9M salt for hybridisation, and at least about 0.5M to at least about 0.9M salt for washing conditions, or high stringency, which includes and encompasses from at least about 31% v/v to at least about 50% v/v formamide and from at least about 0.01M to at least about 0.15M salt for hybridisation, and at least about 0.01M to at least about 0.15M salt for washing conditions.

Accordingly, another aspect of the present invention contemplates a variant HBV exhibiting reduced sensitivity to a nucleoside analogue and reduced interactivity to an antibody to wild-type HBV surface antigen, said HBV variant characterised by one or more of the following characteristics:

- (i) a nucleotide sequence of its genome as set forth in SEQ ID NO:17 or a sequence having at least 60% similarity thereto;
- (ii) a nucleotide sequence capable of hybridising to SEQ ID NO:17 under low stringency conditions at 42°C;
- (iii) a mutation in an overlapping portion of open reading frames for DNA polymerization and HBV surface antigen; and
- (iv) a mutation in the B and/or C domain of HBV DNA polymerase and is a region corresponding to amino acids 118 to 169 and also 169 to 207 of HBV surface antigen.

According to another aspect of the present invention, there is provided a variant HBV comprising a nucleotide sequence which encodes a DNA polymerase having the amino acid sequence: (SEQ ID NO: 27) and (SEQ ID NO: 28)

X<sub>1</sub>HPX<sub>2</sub>LGX<sub>3</sub>RKX<sub>4</sub>PMGX<sub>5</sub>GLSX<sub>6</sub>FLX<sub>7</sub>AQFTSAX<sub>8</sub>X<sub>9</sub> .....

- 9 -

$$X_{10}FX_{11}YX_{12}DDX_{13}VLGAX_{14}X_{15}$$

wherein

5  $X_1$  is S or A;  
 $X_2$  is I or V;  
 $X_3$  is F or L;  
 $X_4$  is I or L;  
 $X_5$  is L or Y or G;  
 $X_6$  is P or L;  
 $X_7$  is L or M;  
10  $X_8$  is I or L;  
 $X_9$  is C or L;  
 $X_{10}$  is A or V;  
 $X_{11}$  is S or A;  
 $X_{12}$  is M or I or V;  
15  $X_{13}$  is V or L or M;  
 $X_{14}$  is K or R; and/or  
 $X_{15}$  S or T;

and wherein said variant exhibits reduced sensitivity to a nucleoside sensitivity to a nucleoside  
 20 analogue, such as famciclovir (penciclovir) and/or lamivudine (3TC).

Another embodiment of the present invention is directed to a variant HBV comprising a  
 nucleotide sequence which encodes a surface antigen having at least one amino acid substitution,  
 addition and/or deletion to amino acid residue numbers 118 to 169 and also 169 to 207 of said  
 25 surface antigen which corresponds to a DNA polymerase having the amino acid sequence:

SEQ ID NO: 43)

~~X<sub>16</sub>TX<sub>17</sub>X<sub>18</sub>KLHLX<sub>19</sub>X<sub>20</sub>HPX<sub>21</sub>LGX<sub>22</sub>RKX<sub>23</sub>PMGX<sub>24</sub>GLSX<sub>25</sub>FLX<sub>26</sub>AQFTSAX<sub>27</sub>X<sub>28</sub>.....~~

$X_{10}FX_{11}YX_{12}DDX_{13}VLGAX_{14}X_{15}$

30 wherein:  $X_{16}$  is Q or K;  
 $X_{17}$  is Y or F;

- 10 -

X<sub>18</sub> is G or E;X<sub>19</sub> is R or W or ~~K~~<sup>E</sup>;X<sub>20</sub> is Y or L;X<sub>21</sub> is S or A;5 X<sub>22</sub> is I or V;X<sub>3</sub> is F or L;X<sub>4</sub> is I or L;X<sub>5</sub> is L or V or G;X<sub>6</sub> is P or L;10 X<sub>7</sub> is L or M;X<sub>8</sub> is I or L;X<sub>9</sub> is C or L;X<sub>10</sub> is A or V;X<sub>11</sub> is S or A;15 X<sub>12</sub> is M or I or V;X<sub>13</sub> is V or L or M;X<sub>14</sub> is K or R; and/orX<sub>15</sub> S or T;

20 and wherein said variant exhibits reduced interactivity with immunological reagents, such as an antibody, to said surface antigen.

Examples of preferred variants comprise the amino acid sequences shown in Figure 4. An example of a particularly preferred mutant is shown in Figure <sup>6</sup>~~5~~<sub>1</sub> (SEQ ID NO:17).

25

The identification of the variants of the present invention permits the generation of a range of assays to detect such variants. The detection of such variants may be important in identifying resistant variants to determine the appropriate form of chemotherapy and/or to monitor vaccination protocols.

30

Accordingly, another aspect of the present invention contemplates a method for determining the

potential for an HBV to exhibit reduced sensitivity to a nucleoside analogue, said method comprising isolating DNA or corresponding mRNA from said HBV and screening for a mutation in the nucleotide sequence encoding HBV DNA polymerase resulting in at least one amino acid substitution, deletion and/or addition in the B domain or C domain or a region proximal thereto  
 5 of said DNA polymerase wherein the presence of such a mutation is an indication of the likelihood of resistance to said nucleoside analogue.

A further aspect of the present invention provides a method for determining the potential for an HBV to exhibit reduced interactivity to antibody to HBV surface antigen, said method  
 10 comprising isolating DNA or corresponding mRNA from said HBV and screening for a mutation in the nucleotide sequence encoding HBV surface antigen resulting in at least one amino acid substitution, deletion and/or addition in amino acids 118 to 169 and/or 169 to 207 of said surface antigen or a region proximal thereto of said surface antigen wherein the presence of such a mutation is an indication of the likelihood of reducing interactivity of said antibodies to said  
 15 mutated surface antigen.

Preferably, the assay determines a mutation resulting in a Glu/Val519Leu substitution and/or a Leu526Met substitution and/or a Pro523Leu substitution and/or a ~~S559T~~ <sup>Ser569Thr</sup> substitution, and/or Gly498Glu substitution, and/or Arg/Trp499 <sup>Glu</sup> ~~Lys~~ substitution.

20

The DNA or corresponding RNA may be assayed or alternatively the DNA polymerase or surface antigen may be screened for the mutation.

The detection according to this aspect of the invention may be any nucleic acid-based detection  
 25 means, for example nucleic acid hybridisation techniques or polymerase chain reaction (PCR). The invention further encompasses the use of different assay formats of said nucleic acid-based detection means, including restriction fragment length polymorphism (RFLP), amplified fragment length polymorphism (AFLP), single-strand chain polymorphism (SSCP), amplification and mismatch detection (AMD), interspersed repetitive sequence polymerase chain reaction (IRS-  
 30 PCR), inverse polymerase chain reaction (iPCR) and reverse transcription polymerase chain reaction (RT-PCR), amongst others.

The present invention extends to a range of immunologically based assays to detect variant HBV DNA polymerase or surface antigen. These assays are based on antibodies directed to naturally occurring HBV DNA polymerase or surface antigen which do not, or substantially do not, interact with the variant HBV DNA polymerase or surface antigen. Alternatively, antibodies to  
5 a variant HBV DNA polymerase or surface antigen are used which do not or substantially do not, interact with naturally occurring HBV DNA polymerase or surface antigen.

Monoclonal or polyclonal antibodies may be used although monoclonal antibodies are preferred as they can be produced in large quantity and in a homogenous form. A wide range of  
10 immunoassay techniques are available such as described in U.S. Patent Nos. 4,016,043, 4,424,279 and 4,018,653.

The detection of amino acid variants of DNA polymerase is conveniently accomplished by reference to the consensus amino acid sequence shown in Figure 4. The polymorphisms shown  
15 represent the variations shown in various data bases for active pathogenic HBV strains. Where an HBV variant comprises an amino acid different to what is represented, then such an isolate is considered a putative HBV variant having an altered DNA polymerase activity.

Accordingly, another aspect of the present invention contemplates a method for determining  
20 whether an HBV isolate encodes a variant DNA polymerase, said method comprising determining the amino acid sequence of its DNA polymerase directly or *via* a nucleotide sequence and comparing same to the amino acid sequence below: (SEQ ID NO: 29)  
A

## DOMAIN A

421                      430                      440                      450  
S<sup>N</sup><sub>D</sub>LSWLSLD VSAAFYH<sup>I</sup><sub>P</sub>PL HPAAMPHLL<sup>I</sup><sub>V</sub> GSSGL<sup>S</sup><sub>D</sub>RYVA

460                      470                      480                      490  
 RLSS<sup>T</sup><sub>NS</sub>R<sup>N</sup><sub>N</sub>I<sup>N</sup>\*N NYH<sup>O</sup><sub>H</sub>Y<sup>G</sup><sub>R</sub>\*\*\*D<sup>N</sup><sub>LH</sub> D<sup>S</sup><sub>N</sub>YCSR<sup>N</sup><sub>Q</sub>LYVS LL<sup>M</sup><sub>LLY</sub>K<sup>Q</sup><sub>T</sub>Y<sup>F</sup><sub>GR</sub>W

## DOMAIN B

500                      510                      520                      530  
KLHL<sup>Y</sup><sub>L</sub>SAHPI<sup>I</sup><sub>V</sub> LGFRK<sup>I</sup><sub>L</sub>PMG<sup>V</sup><sub>G</sub> GLSPFLLAQF TSAIC<sup>L</sup><sub>A</sub>S<sup>V</sup><sub>M</sub>V<sup>T</sup><sub>RCR</sub>

## DOMAIN C

540                      550                      560  
AF<sup>F</sup><sub>PHCL</sub>V<sup>A</sup><sub>VFS</sub>AY MDD<sup>V</sup><sub>L</sub>MVLGA<sup>K</sup><sub>RS</sub>T V<sup>G</sup><sub>Q</sub>EH<sup>L</sup><sub>S</sub>RES<sup>S</sup><sub>FL</sub>Y<sup>T</sup><sub>AS</sub>

## DOMAIN D

## DOMAIN E

570                      580                      590                      600  
V<sup>I</sup><sub>T</sub>C<sup>N</sup><sub>S</sub>FVLLS<sup>D</sup><sub>L</sub>VGI HLNP<sup>N</sup><sub>Q</sub>KTKRW GYSLNFMGY<sup>V</sup><sub>I</sub>I G

- 14 -

where the presence of a different amino acid from the consensus sequence indicates a putative HBV variant.

The present invention further contemplates agents which mask the nucleoside analogue resistance mutation. Such agents will be particularly useful in long term treatment by nucleoside analogues. The agents may be DNA or RNA or proteinaceous or non-proteinaceous chemical molecules. Natural product screening such as from plants, coral and microorganisms is also contemplated as a useful potential source of masking agents. The agents may be in isolated form or in the form of a pharmaceutical composition and may be administered sequentially or simultaneously with the nucleoside analogue.

The subject invention extends to kits for assays for variant HBV. Such kits may, for example, contain the reagents from PCR or other nucleic acid hybridisation technology or reagents for immunologically based detection techniques.

The present invention is further described by the following non-limiting figures and examples.

In the figures:

**Figure 1** is a diagrammatic representation showing the partially double stranded DNA HBV genome showing the overlapping open reading frames encoding surface (S), core (C), polymerase (P) and X gene.

**Figure 2** is a graphical representation showing serum biochemical (ALT) and virological (HBV DNA) profile in the transplant patient and the responses following the introduction of various antiviral treatment programs. Treatment GCV + PFF, GCV and FCV[I] and FCV[II] are described in detail in the examples. Treatment GCV + PFF is ganciclovir plus foscarnet combination (12), treatment GCV is parenteral ganciclovir maintenance therapy and treatment FCV[I] and FCV[II] is oral famciclovir therapy at a dose of 250 mg or 500 mg twice daily, respectively. The day each therapy commenced is shown in brackets. The ALT (••) and the HBV DNA (□-□) responses are plotted against time from the commencement of antiviral

- 15 -

therapy at 6 months post-OLT. The five key time points for the sequence analysis, pre-treatment (PRE-) and days 87, 600, 816 and 1329 post antiviral treatment are shown.

**Figure 3** is a representation showing amino acid alignment of the RNA dependent DNA polymerase sequence motifs from HBV, pre-treatment with famciclovir and 370 days post-treatment (total antiviral therapy of 816 days), with the woodchuck hepatitis virus (WHV), human immunodeficiency virus (HIV), and the comparable regions with the DNA polymerase of herpes simplex virus (HSV) (13, 14). <sup>(SEQ ID NOS: 30-37)</sup> The conserved asparagine (D) and glycine (G) residues within the polymerase motifs are in bold type and the amino acid changes found after famciclovir treatment are in bold type and underlined. The location of the mutated amino acid residues within HBV polymerase are shown. The bold face underlined glycine (G) residue in the HSV polymerase becomes a cysteine (C) during penciclovir treatment (15).

**Figure 4** is a representation showing conserved regions of domain A to E (underlined) of HBV. M in YMDD is designated amino acid number 550. \* indicates greater than three amino acid possibilities at this position of the consensus sequence. <sup>(SEQ ID NOS: 29)</sup>

**Figure 5** is a representation showing amino acid alignment of the RNA dependent DNA polymerase sequence motifs from HBV, noting the amino acid changes which have been selected for in the presence of famciclovir and 3TC. <sup>(SEQ ID NOS: 36-41) and SEQ ID NOS: 45-49)</sup> HBV consensus sequence was derived from published sequences in Genbank/Entrez. The conserved asparagine (D) and glycine (G) residues within the polymerase motifs are in bold type. The amino acid changes found after famciclovir treatment are in bold green type and underlined and after 3TC are in bold blue type and are underlined. The amino acid sequence of the HBV isolated from patient A and patient B, during famciclovir treatment, and from Patient C who did not respond to famciclovir and was later treated with 3TC <sup>and</sup> in which a resistance mutation was selected (3TC 2). The published 3TC changes detected by Ling *et al* (16) is shown in 3TC 1.



- 16 -

(SEQ ID NO: 17)

Figure 6 is a representation showing the nucleotide sequence of an HBV variant and corresponding amino acid sequences for HBV DNA polymerase and HBV surface antigen showing in bold mutations **G498E** in the polymerase and **D144E** and **G145R** in the surface antigen.

5

## EXAMPLE 1 CASE STUDY

### 1. PATIENT A

- 5 The inventors sequenced the HBV polymerase and X open reading frames from a series of isolates from a patient who received antiviral therapy for almost 4 years following post liver transplant recurrence of HBV infection (Figure 2).

The patient (male, aged 42 years) was transplanted because of end-stage liver failure due to chronic HBV infection. The initial post transplant course was unremarkable but by 5 months there was evidence of recurrent infection and very high levels of viral replication and deteriorating liver function (12). The histological picture was consistent with fibrosing cholestatic hepatitis. Antiviral treatment was commenced approximately 6 months post-OLT. Initially, the patient received intravenous (iv) ganciclovir (GCV; 10 mg/kg/day) in combination with iv foscarnet (PFF; 50-125 mg/kg/day; the dose depending on renal function) (12). This is the treatment of GCV+ PFF described in Figure 7 which lasted for 86 days. Maintenance iv GCV (3.3-6.7 mg/kg/day) three times per week was commenced on day 87 of antiviral treatment (GCV in Figure 7). Oral famciclovir (250 mg, twice daily) was commenced on day 446 of therapy (FCV [I] in Figure 7) which was increased to 500 mg twice daily (FCV [II] in Figure 1) on day 500. The patient is currently on this treatment regime. The clinical and virological details of this patient preceding famciclovir therapy have been reported (12).

Serum samples were routinely collected and stored at -70°C. Informed consent was obtained from the patient to use these samples for research purposes. Figure 2 shows the alanine amino transferase (ALT) and HBV DNA levels over the entire course of antiviral treatment. The 5 samples chosen for additional studies cover a period of almost four years.

### 2. PATIENT B

Patient B was retransplanted for pre-core mutant associated HBV-related allograft loss 14 months after the initial liver transplant. Antiviral treatment with GCV (7.5 mg/kg/day) was given for 10 months and then ceased. This was followed by oral famciclovir therapy given (500 mg

- 18 -

3 times/day).

From patient B the entire HBV polymerase gene was sequenced from a serum HBV sample taken post-transplantation after 850 days FCV therapy. The regions encompassing the catalytic 5 domains of the HBV polymerase were sequenced from a serum sample pretransplant prior to FCV treatment.

### 3. PATIENT C

This patient did not respond to famciclovir and was later treated with lamivudine (3TC) (6, 7) 10 in which a resistance mutation was selected.

### 4. PATIENT D

This patient is treated with famciclovir in which resistance mutation is selected.

15

## EXAMPLE 2

### VIRAL MARKERS IN SERUM

Hepatitis B surface antigen (HbsAg), hepatitis B e antigen (HbeAg), anti-HBe, hepatitis B core antigen (HbcAg) specific IgG and IgM, hepatitis A specific IgM, hepatitis delta antigen and 20 antibody, and anti-hepatitis C virus antibody were measured using commercially available immunoassays (Abbott Laboratories, North Chicago, IL). Only the HBV markers were positive. Hepatitis B viral DNA levels were measured and quantified using a capture hybridisation assay according to the manufacturer's directions (Digene Diagnostics Inc., Beltsville, MD). This patient was infected with a pre-core HBV mutant pre-OLT (12) and this status did not change 25 post-OLT.

## EXAMPLE 3

### SEQUENCING AND CLONING OF HBV DNA

- 30 1. **Extraction of DNA from sera:** Aliquots of 50  $\mu$ l of sera were mixed with 150  $\mu$ l TE (10 mmol/L Tris-HCl (pH 7.5), 2 mmol/L EDTA), 1% w/v sodium dodecyl sulfate and 1 mg/ml

pronase and incubated at 37°C for 2 hours. DNA was deproteinised by phenol/chloroform, precipitated with isopropanol and dissolved in 25 µl nuclease-free water.

2. **Amplification of the viral polymerase and X genes by polymerase chain reaction**  
 5 (PCR): Oligonucleotides were synthesised by Bresatec, Adelaide, Australia. For amplification of the polymerase gene, the sense primer was 5'- GGA GTG TGG ATT CGC ACT CC -3' [SEQ ID NO:1] (nucleotides [nt] -40 to -21) and the antisense primer was 5'- GCT CCA AAT TCT TTA TA -3' [SEQ ID NO:2] (nt 2831 to 2847). For amplification of the X gene, the sense primer was 5'-CCT TTA CCC CGT TGC CCG GC -3' [SEQ ID NO:3] (nt 2055 to 2074) and  
 10 the antisense primer 5'- GCT CCA AAT TCT TTA TA -3' [SEQ ID NO:4] (nt 2831 to 2847). All nt are numbered from the start of the polymerase gene. Each reaction was carried out using 5 µl of the extracted DNA as template, 1.5 U of *Taq* polymerase (Perkin Elmer Cetus, Norwalk, CT), 1 µmol/L of sense and antisense primers, 200 µmol/L each of deoxynucleoside triphosphates, 50 mmol/L KCl, 3.5 mmol/L MgCl<sub>2</sub>, 10 mmol/L Tris-HCl (pH 8.3) and 0.01% w/v  
 15 gelatin. Amplification was achieved by 40 cycles of denaturation (94°C for 1 min), annealing (55°C for 1 min) and extension (72°C for 1.5 min), followed by a final extension of 7 min (Perkin-Elmer Cetus, Norwalk, CT). The PCR product was analysed by gel electrophoresis through 1.5 % w/v agarose and visualised by UV irradiation after staining with ethidium bromide.

20

3. **Sequencing of the polymerase and X genes of HBV DNA:** The specific amplified product was purified using Geneclean II (BIO 101 Inc., La Jolla, CA) and directly sequenced using Sequenase version 2.0 (United States Biochemical Corp., Cleveland, OH). The PCR primers were used as sequencing primers and internal primers were additionally synthesised to  
 25 sequence the internal regions of the PCR products. The following internal and sequencing primers were used 5'- GCC GCG TCG CAG AAG ATC TCA AT -3' [SEQ ID NO:5] (nt 104-126), 5'- GGT TCT ATC CTA ACC TTA CC -3' [SEQ ID NO:6] (nt 341-360), 5'- GCC TCA TTT TGT GGG TCA CCA TA -3' [SEQ ID NO:7] (nt 496-518), 5'- TGG GGG TGG AGC CCT CAG GCT -3' [SEQ ID NO:8] (nt 731-751), 5'- CAC AAC ATT CCA CCA AGC TC  
 30 -3' [SEQ ID NO:9] (nt 879-899), 5'- AAA TTC GCA GTC CCC AAC -3' [SEQ ID NO:10] (nt 1183-1195), 5'- GTT TCC CTC TTC TTG CTG T -3' [SEQ ID NO:11] (nt 1429-1447),

- 20 -

5'- TTT TCT TTT GTC TTT GGG TAT -3' [SEQ ID NO:12] (nt 1683-1703) 5'-CCA ACT  
TAC AAG GCC TTT CTG-3' [SEQ ID NO:13] (nt 1978-1999), 5'-CAT CGT TTC CAT GGC  
TGC TAG GC-3' [SEQ ID NO:14] (nt 2239-2262).

#### 5 4. Cloning of the HBV polymerase gene into pUC18:

Due to the small amount of HBV DNA in the samples, the region encompassing nt 1429 to 1703 from the HBV polymerase gene were amplified by PCR using the primers -5'-GTT TCC CTC TTC TTG CTG T-3' [SEQ ID NO:15] (nt 1429-1447) and 5' ATA CCC AAA GAC AAA AGA AAA- 3' [SEQ ID NO:16] (nt 1703-1683), before cloning. The DNA was purified with  
10 GeneClean II and ligated using T4 DNA ligase (New England Biolabs, Beverly, MA) into a *Sma* I - digested dephosphorylated pUC18 plasmid (Pharmacia Biotech, NJ). Clones were directly sequence as above.

#### EXAMPLE 4

#### 15 DNA POLYMERASE ASSAY

Samples of serum (100  $\mu$ l) were applied to a 20% w/v sucrose cushion in TNE (20 mmol/L Tris-HCl pH 7.4, 150 mmol/L NaCl, 1 mmol/L EDTA) and centrifuged at 200,000 g for 3 hr at 10°C using an SW41 rotor in a Beckman Model L8 ultracentrifuge. The pellet was resuspended in 50  
20 mmol/L TRIS-HCl pH 7.5 containing 1.5% v/v Triton-X100, 100 mmol/L KCl and 0.01% v/v 2-mercaptoethanol and allowed to stand overnight at 4°C. Small aliquots of the suspension were assayed for endogenous HBV DNA polymerase activity essentially as described by Price *et al* (16). Each assay was performed in a total volume of 30  $\mu$ l which contained 20  $\mu$ l of the partly purified HBV and (final concentrations) 30 mmol/L Tris-HCl pH 7.5, 30 mmol/L MgCl<sub>2</sub>, 10  
25  $\mu$ mol/L each dATP, dTTP and dGTP, and 0.01  $\mu$ M [ $\alpha$ -<sup>32</sup>P]-dCTP (3,000 Ci/mmol) (Dupont NEN, Boston, MA). To test for penciclovir triphosphate (PCV-TP) sensitivity, paired assays were performed on each sample, with an excess (100  $\mu$ mol/L penciclovir-triphosphate included in the reaction mixture in one assay of each pair. After 2 hr at 37°C, reactions were stopped by spotting 20  $\mu$ l aliquots of each reaction mix onto 25mm diameter glass fibre discs (Advantex,  
30 Tokyo, Japan) which had been pre-soaked in 10% w/v trichloroacetic acid (TCA). Discs were dried before washing in ice-cold 10% w/v TCA containing 10 mmol/L sodium pyrophosphate.

Three further 10 min washes in cold 5% v/v TCA followed. The washed discs were finally rinsed in absolute ethanol, air dried, and counted for radioactivity. Inhibition of HBV DNA polymerase activity by PCV-TP was expressed as the percentage difference in activity in the assay mix containing PCV-TP compared to the matched control. Because of limited sample amounts, it was not possible to standardize enzyme activity or to perform replicate assays. Despite the inherent variability of the assay, a general time related decrease in sensitivity of the HBV DNA polymerase to PCV-TP was evident (see Table 1).

#### EXAMPLE 5

##### EFFECT OF ANTIVIRAL THERAPY

Upon commencement of the antiviral treatment strategy GCV+ PFF, the level of HBV DNA post-OLT decreased from over 100,000 pg/ml to 10,800 pg/ml by day 87 (Figure 1). This reduction in viraemia was associated with clinical, biochemical and histological improvement (12). Maintenance famciclovir therapy (treatment GCV) resulted in fluctuating levels of HBV DNA over the ensuing 359 days with two peaks of HBV DNA observed. The switch to oral famciclovir on day 446 was also associated with a rise in HBV DNA, but this was likely to have been the result of insufficient dosing (FCV[I] in Figure 2) rather than a breakthrough in treatment. Following dose increase to FCV [II] on day 500, there was a decrease in HBV DNA. However, the level of HBV DNA gradually rose over time from 3,000 pg/ml on day 600 (154 days of famciclovir), to 8,800 pg/ml on day 816 (370 days famciclovir), peaking at 29,000 pg/ml on day 1302 (856 days of famciclovir), then stabilising at around 12,000 pg/ml on day 1329 (883 days of famciclovir). A students test of the DNA levels during the treatment period from days 816 to days 1329, revealed statistically significant rise. There was a 1.5 to 2 fold rise in ALT levels over the same time interval (Figure 2) and no change in clinical status.

#### EXAMPLE 6

##### NUCLEOTIDE CHANGES

The X and the polymerase genes of HBV were sequenced at five time points (Figure 2). During almost 4 years of the antiviral therapy there were no changes in the X gene compared to the

- 22 -

pretreatment sequence. However, there were 5 nt changes detected in the polymerase gene from day 816 and day 1329 samples (Table 1). These changes were detected in separate independent PCR amplifications; furthermore the mutations were detected by sequencing both strands and are therefore unlikely to be the result of PCR generated errors. The nt changes in the polymerase gene were first detected after 816 days of treatment, when the patient had been treated with famciclovir for 370 days. However, only two nt changes, at positions 1498 and 1519 resulted in amino acid changes, Val 519- Leu and Leu 526- Met, respectively. These two nt changes appeared concurrently. At 816 days, three different nt (C,G,T) were detected at position 1498 (all of which would result in a Val to Leu change). After 1329 days post-treatment, thymidine was the dominant species at nt 1498. The amino acid changes at 816 and 1329 days post treatment coincided with reduced serum HBV DNA polymerase sensitivity to PCV-TP (Table 1). These nt changes were not found in 6 patients with post-OLT recurrent HBV infection who were not undergoing FCV therapy.

The region encompassing the nt mutations which gave rise to amino acid changes from the sample taken at 1329 days was cloned and sequenced. Three quasi-species were detected. Seventy-five percent (15/20) of the clones contained both the 1498 and 1519 mutations which occurred together. Pretreatment non-mutated sequences were detected in 3/20 of the clones. A further mutation at nt 1511, which would result in a proline to leucine change at position 523, was detected in 2/20 of the clones. This mutation was not detected with the two dominant mutations, 1498 (Val 519-Leu) and 1519 (Leu 526-Met), nor was it detected by direct PCR sequencing, indicating it probably occurs at a low frequency. Viral DNA from the sample obtained at 600 days (150 days of FCV treatment) was also cloned and sequenced; however, only the pre-treatment sequences were detected.

25

#### EXAMPLE 7

#### NUCLEOTIDE CHANGES IN PATIENTS B, C AND D

The amino acid changes in HBV isolated from patients B and C are shown in Figure 5, and from patient D is shown in Figure 6. In Figure 5, patient A is the same as shown in Figure 3.

- 23 -

Patient B was undergoing long term famciclovir treatment (>850 days). The amino acid change selected during famciclovir treatment is shown as HBV (patient B) in Figure 5. Patient C did not respond to famciclovir and was later treated with 3TC (lamivudine [6,7]). The HBV isolated during FCV treatment from patient C, is shown as HBV (patient C-FCV). All 3TC resistance mutations which developed during treatment with 3TC is shown as HBV (patient C-3TC). The sequence analysis showed a mutation (Thr-Ser substitution) in the HBV polymerase gene near the C domain but no mutation was initially detected in the YMDD motif. A mutation of Met 550 to Ile in the YMDD motif was detected from HBV isolated 32 days (333 days post treatment) after the HBV containing the Thr-Ser substitution was isolated.

10

#### EXAMPLE 8 ESCAPE MUTANTS

Using the method hereinbefore described, HBV variants are screened for escape mutations. These are mutations in surface components such as the HBV surface antigen which reduce the interactivity of the surface component to antibodies or other immunological reagents. Given the overlapping open reading frame of HBV genome, a single mutation may have multiphenotypic consequences. For example, a mutation in the HBV DNA polymerase may also have an affect on the HBV surface antigen.

20

Preferred mutations in the HBV surface antigen are in amino acids 118 to 169 and/or 169 to 207 such as D144E or G145R. These correspond to DNA polymerase mutations G498E and V499L.

A particularly preferred escape mutant and nucleoside analogue resistant mutant has a nucleotide sequence set forth in Figure 6 with corresponding amino acid sequences for the DNA polymerase and surface antigen.

Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. It is to be understood that the invention includes all such variations and modifications. The invention also includes all of the steps, features, compositions and compounds referred to or indicated in this specification,

24



individually or collectively, and any and all combinations of any two or more of said steps or features.

00306430 050609  
663050 05490560

25

**TABLE 1**  
**Nucleotide mutations in the polymerase gene and the resulting**  
**amino acid changes during antiviral therapy**

Days of antiviral treatment	Days post famciclovir treatment	POLYMERASE GENE						Inhibition of HBV DNA Polymerase by PCV-TP**
		nt 297	nt 1498	nt 1511*	nt 1519	nt 2008	nt 2331	
Pretreatment	NR***	T	G	C	C	C	G	40 %
87	NR	-	-	-	-	-	-	NA****
600	154	-	-	-	-	-	-	30 %
816	370	-	G, T, C	-	A	-	-	0 %
1329	883	C	T	T	A	A	A	0 %
Amino acid change		None	Val 519- Leu	Pro 523- Leu	Leu 526- Met	None	None	

The dashes indicate no change from the pre-treatment nucleotide.

\* The mutation was only detected after cloning the PCR product after 1329 days of antiviral treatment. It occurred at a low frequency and was present in only 10% of clones.

\*\* The percentage inhibition of HBV DNA polymerase by PCV-TP in the *in vitro* assay as described in the Methods section.

\*\*\* NR- not relevant

\*\*\*\* NA- not assessable

## BIBLIOGRAPHY:

1. Summers J, Mason W. *Cell* (1982) **29**: 403-415.
2. Vere Hodge R.A. *Antiviral Chem Chemother* (1993) **4**: 67-84.
3. Boyd MR *et al* *Antiviral Chem Chemother*. (1987) **32**: 358-363.
4. Kruger T *et al* *Hepatology* (1994) **22**: 219A.
5. Main J *et al*. *J. Viral Hepatitis* (1996) **3**: 211-215.
6. Severini A *et al* *Antimicrobial Agents Chemother* (1995) **39**: 1430-1435.
7. Dienstag JL *et al* *New England J Med* (1995) **333**: 1657-1661.
8. Shaw T, *et al*. *Antimicrobiol Agents Chemother* (1994) **38**: 719-723.
9. Shaw T, *et al*. *Hepatology* (1996) **24**: *in press*.
10. Tsiquaye KN, *et al*. *J. Med Virol* (1994) **42**: 306-310.
11. Boker KHW, *et al*. *Transplantation* (1994) **57**: 1706-1708.
12. Angus P, *et al*. *J. Gastroenterol Hepatol* (1993) **8**: 353-357.
13. Poch O, *et al*. *EMBO J.* (1989) **8**: 3867-3874.
14. Delarue M, *et al*. *Protein Engineering* (1990) **3**: 461-467.
15. Chiou HC, *et al*. *Antiviral Chem Chemother* (1995) **6**: 281-288.
16. Ling R, *et al*. *Hepatology* (1996) **24**: 711-713.
17. Price PM, *et al*. *Hepatology* 1992 **16**: 8-13.

Ins. C27

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

## **BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☒ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**